Phathom Pharmaceuticals IncPHAT
Price$7.08

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $239.7M+333.8% YoYTTM through 30 Jun 2026
Net Income -$99.1MTTM through 30 Jun 2026
Free Cash Flow -$36.9MTTM through 30 Jun 2026

Margins

Current
Gross Margin79.4%
EBITDA Margin-16.7%
Operating Margin-26.6%
Net Margin-41.3%

Returns

28.8%ROE
-51.6%ROA

Balance Sheet Health

Debt / Equity-0.48x
Current Ratio1.92x
Net Debt-$17.9Mnet cash position
Cash & Equivalents$182.5M

Quality Metrics

Altman Z-Score-5.15
Piotroski F-Score4 / 9
FCF Margin-15.4%
Rule of 4016.7
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $175.1M
Diluted EPS-$1.25TTM
'21'22'23'24'25
FY2025: $-3.03

Dividend

No dividend

Capital Allocation

R&D Spend$30.1M
Capex Intensity0.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.